Rhythm's relamorelin meets in Phase II diabetic gastroparesis trial

Rhythm Holding Co. LLC (Boston, Mass.) said twice-daily subcutaneous relamorelin ( RM-131) met the primary endpoint of reducing gastric half-emptying time from baseline to week four vs. placebo in a Phase II trial to treat diabetic gastroparesis (reductions of 23.1 vs. 7.5 minutes, p=0.0295). Relamorelin met a secondary endpoint of significantly reducing weekly average vomit severity score and weekly number of vomiting episodes from baseline to week four vs. placebo. It missed a secondary endpoint of reducing a composite score of subjective gastroparesis symptoms from baseline to week four vs. placebo. The double-blind, U.S. trial enrolled 204 patients with moderate to severe diabetic gastroparesis. Data were presented at the Digestive Disease Week meeting in Chicago. ...